Astria Therapeutics to Present STAR-0215 at the 2023 European Academy of Allergy, Asthma, and Immunology Annual Meeting

BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information on STAR-0215 and its development in three posters at the 2023 European Academy of Allergy, Asthma, and Immunology Annual Meeting in Hamburg, Germany on June 9-11, 2023.

• Nikolaos Biris, Ph.D., Director of Assay Development at Astria Therapeutics, will present “STAR-0215 Bound to Active Plasma Kallikrein Structure Uncovers a New Binding Mode” during a Thematic Poster Session on Friday, June 9, at 12:00pm CET.
• Dr. William Lumry, M.D., Physician and Owner of Allergy & Asthma Specialists of Dallas, will present “Initial Results from a Phase 1a Single Ascending Dose Clinical Trial of STAR-0215, an Investigational Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor for Hereditary Angioedema (HAE), in Healthy Adult Subjects Followed for 3 Months” in a Flash Talks Session on Friday, June 9, at 1:15pm CET.
• Dr. Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité Universitätsmedizin in Berlin and Principal Investigator for the ALPHA-STAR trial, will present “Design of a Phase 1b/2 Proof-of-Concept Trial of STAR-0215 as a Long-Acting Preventative Therapy in Patients with Hereditary Angioedema (HAE) Types I or II” in a Flash Talks Session on Friday, June 9, at 1:15pm CET.

All e-posters will be available to registered attendees on the digital platform during and after the conference, as well as on www.astriatx.com.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.

Contacts

Astria:

Investor relations and media:
Elizabeth Higgins

[email protected]